{{Rsnum
|rsid=1846681
|Gene=ADCY2
|Chromosome=5
|position=7530628
|Orientation=plus
|GMAF=0.4449
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
|Gene_s=ADCY2
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 31.9 | 40.7 | 27.4
| HCB | 27.0 | 48.9 | 24.1
| JPT | 25.0 | 49.1 | 25.9
| YRI | 55.8 | 38.8 | 5.4
| ASW | 54.4 | 43.9 | 1.8
| CHB | 27.0 | 48.9 | 24.1
| CHD | 29.6 | 59.3 | 11.1
| GIH | 19.8 | 53.5 | 26.7
| LWK | 51.8 | 40.9 | 7.3
| MEX | 29.8 | 56.1 | 14.0
| MKK | 38.5 | 51.9 | 9.6
| TSI | 19.6 | 46.1 | 34.3
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs1846681
|Name_s=
|Gene_s=ADCY2
|Feature=
|Evidence=PubMed ID:17537913
|Annotation=Risk or phenotype-associated allele: not stated Phenotype: Using a Quantitative Transmission Disequilibrium Test (QTDT), this variant was significantly associated with etoposide toxicity based upon IC50 values in cell lines from 30 parent-child trios. Study size: 87. Study population/ethnicity: 87 European descent Caucasians. Significance metric(s): p = 0.00003. Type of association: FA; GN.
|Drugs=etoposide
|Drug Classes=
|Diseases=Drug Toxicity
|Curation Level=Curated
|PharmGKB Accession ID=PA165109316
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs1846681
|overall_frequency_n=58
|overall_frequency_d=128
|overall_frequency=0.453125
|n_genomes=37
|n_genomes_annotated=0
|n_haplomes=51
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Illumina Human 1M}}